glp-1 clinical trials recruiting 📣 NOW RECRUITING: New Research Study We are looking for participants for a Phase 3 trial evaluating a new weight-management option! If you've been on a stable (either Wegovy or Clinical efficacy results from clinical

Description

New Starter Bundle benefits: Perfect if on GLP-1 injections 1 product = 1 meal 20+ vitamins & minerals High protein Gluten Free Suitable for vegetarian Product contains: 24x shakes 20x bars 6x meals 6x soup About this item: Preparing a balanced 200 kcal meal can be challenging, especially when maximising health benefits alongside GLP-1 injections

Available in Two Sizes: 1-Pack (30 patches): Compact and convenient for customers seeking a simple daily solution, priced at $8.99

The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications